

- Furtado, P. B., Whitty, P. W., Robertson, A., Eaton, J. T., Almogren, A., Kerr, M. A., et al. (2004). Solution structure determination of monomeric human IgA2 by x-ray and neutron scattering, analytical ultracentrifugation and constrained modelling: a comparison with monomeric human IgA1. *Journal of Molecular Biology*, 338(5), 921–941.
- Guo, D. L., Gao, A., Michels, D. A., Feeney, L., Eng, M., Chan, B., et al. (2010). Mechanisms of unintended amino acid sequence changes in recombinant monoclonal antibodies expressed in Chinese hamster ovary (CHO) cells. *Biotechnology and Bioengineering*, 107(1), 163–171.
- Janeway, C. A., Travers, P. A., Walport, M., & Shlomchik, M. J. (2001). *Immunobiology*. New York: Garland Press.
- Jefferis, R., Lund, J., & Pound, J. D. (1998). IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. *Immunological Reviews*, 163, 59–76.
- Junutula, J. R., Raab, H., Clark, S., & Sunil, B. (2008). Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. *Nature Biotechnology*, 26(8), 8.
- Liu, H. C., Gaza-Bulsecu, G., Faldu, D., Chumsae, C., & Sun, J. (2008). Heterogeneity of monoclonal antibodies. *Journal of Pharmaceutical Sciences*, 97(7), 2426–2447.
- Mattu, T. S., Pleass, R. J., Willis, A. C., Kilian, M., Wormald, M. R., Lellouch, A. C., et al. (1998). The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions. *Journal of Biological Chemistry*, 273(4), 2260–2272.
- Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S. P., Goodall, M., et al. (2001). Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. *Journal of Biological Chemistry*, 276(49), 45539–45547.
- Oda, M. (2004). Antibody flexibility observed in antigen binding and its subsequent signaling. *Journal of Biological Macromolecules*, 4(2), 45–56.
- Presta, L. (2003). Antibody engineering for therapeutics. *Current Opinion in Structural Biology*, 13(4), 519–525.
- Raju, T. S., Briggs, J. B., Borge, S. M., & Jones, A. J. S. (2000). Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. *Glycobiology*, 10(5), 477–486.
- Reuters. (2014). *Research and markets: Global and Chinese monoclonal antibody industry report, 2013–2017*. From <http://www.reuters.com/article/2014/01/07/research-and-markets-idUSnBw075871a+100+BSW20140107>.
- Tao, M., & Morrison, S. (1989). Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. *Journal of Immunology*, 143, 2595–2601.
- Wang, W., Singh, S., Zeng, D. L., King, K., & Nema, S., et al. (2007). Antibody structure, instability, and formulation. *Journal of Pharmaceutical Sciences*, 96(1), 1–26.
- Wankanker, A. (May 2010). *Antibody drug conjugates: The next wave of monoclonal antibody-mediated chemotherapeutics*. AAPS News Magazine.
- Weitzhandler, M., Hardy, M., Co, M. S., & Avdalovic, N. (1994). Analysis of carbohydrates on IgG preparations. *Journal of Pharmaceutical Sciences*, 83(12), 1670–1675.
- Wen, J., Jiang, Y., & Nahri, L. (2008). Effect of carbohydrate on thermal stability of antibodies. *American Pharmaceutical Review*.
- Woof, J. M., & Burton, D. R. (2004). Human antibody-Fc receptor interactions illuminated by crystal structures. *Nature Reviews Immunology*, 4(2), 89–99.